Life Sciences Industry Leader Dr. David H. Crean Releases His New Book That Addresses Biopharma’s High-Stakes Leadership Gap
San Diego, California, United States – September 17, 2026- Renowned life sciences executive and advisor Dr. David H. Crean is here to release his book, Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences. Drawing from extensive experience at the intersection of life sciences dealmaking and corporate strategy, this book is projected to offer a framework designed to help biopharma industry leaders who are struggling between technical research, institutional finance, and corporate governance.
In an industry where fewer than 8 percent of Phase I therapeutics reach regulatory approval, Dr. Crean argues that leadership failures cause the majority of pipeline collapses. Dual Fluency addresses the growing divide between technical founders and capital-native investors, equipping leaders to hold both sides of the strategic conversation simultaneously.
Key Perspectives from Dr. David H. Crean:
- Closing the Translation Gap: Dr. Crean identifies how communication breakdowns between R&D teams and financial investors lead to misallocated capital and lost enterprise value.
- Navigating Market Shifts: The author outlines how converging forces—including AI-native drug discovery, complex capital stacks, and fractional executive models—make dual fluency an operational necessity.
- Empowering Scientist-Founders: Dr. Crean provides actionable strategies for academic entrepreneurs and pre-commercial CEOs to acquire capital fluency without sacrificing scientific rigor.
- Elevating Boardroom Governance: The book details how board members can move beyond traditional credentialing to active risk reduction and capital stewardship.
The life sciences industry produces scientific breakthroughs at an unprecedented rate. But we should not neglect the shortage of leaders who can translate those breakthroughs into funded, governed, and commercialized medicines. Acquiring Dual Fluency ensures that groundbreaking science survives the transition from bench to boardroom and helps today’s biopharma leaders navigate modern dilemmas.
Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences will soon be available on Amazon and at leading bookstores.
About the Author:
David H. Crean, PhD, MBA, is Founder and Managing Partner of Cardiff Advisory LLC, a boutique life sciences M&A and strategic advisory firm based in San Diego, CA. Over three decades, he has closed more than fifty transactions spanning M&A, licensing, partnering, and capital raises across numerous therapeutic area disciplines.
A former senior executive at Allergan, he also serves as Fractional Chief Business Officer of MediciNova, Inc. (NASDAQ: MNOV), co-founded CEO360, and holds FINRA Series 79 and 63 registrations.
Dr. Crean has advised and mentored more than 250 life sciences CEOs, boards of directors, and entrepreneurs over the past five years on issues of growth and exit. He has been named five consecutive times to the San Diego Business Journal SD500 Most Influential list.
Book Name: Dual Fluency: The Language of Science and Capital in Life Sciences
Author Name: David H. Crean
ISBN Number: 979-8952851153
Kindle Version: Click Here
Paperback Version: Click Here
Media Contact
Company Name: American Publishers Inc
Contact Person: Media Relations
Email: Send Email
Phone: +1(818)483-1118
Address:12100 Wilshire Boulevard, 8th Floor
City: Los Angeles
State: CA 90025
Country: United States
Website: https://americanpublishersinc.com/
